Health disparities are shortening lives by decades in high- and low-income countries alike, the World Health Organization says.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
A study of 30 million people in the United Kingdom finds that 0.4% of people who completed their primary COVID-19 vaccine series had severe breakthrough infections, compared with 0.2% of booster recipients, during Omicron variant predominance.
Nearly three of four US high school students report one or more adverse experiences contributing to poor mental health and suicidal behaviors amid the COVID-19 pandemic, according to a survey published today in Morbidity and Mortality Weekly Report (MMWR).
Study finds a considerable burden of fatigue and "brain fog" in COVID long-haulers.
The vaccine, which targets Omicron subvariants, is approved for kids as young as 5.
One study shows a link between symptomatic COVID-19 and poor quality of life later on.
COVID-19 vaccination may protect pregnant women and their fetuses against virus-related placentitis (inflammation of the placenta) and stillbirth, concludes a review study published today in the American Journal of Obstetrics & Gynecology. The research will also be presented next week at ID Week in Washington, DC.
People lied mostly over a desire for normalcy and personal freedom.
A new global estimate of people who experienced long-COVID symptoms after having symptomatic COVID infection suggests that 6.2% reported one of three long-term symptom clusters, an international research group reported yesterday in JAMA.
Omicron was tied to a lower risk of maternal critical care (0.3% vs 1.8%) and preterm birth (1.8% vs 4.2%).
A US study of almost 17,000 patients finds modest two-dose Pfizer COVID vaccine effectiveness (VE) against hospitalization and emergency department (ED) admission for Omicron BA.1 (the original Omicron variant) and the BA.2 subvariant, but three-dose VE was 79% and 71% for hospitalization, respectively, and 72% and 21% for ED visits.
